Pharmaceutical Company Value Streams

This package includes 22 end-to-end value stream maps for a pharmaceutical company, delivered as an editable PowerPoint deck. Each flow, from early discovery through clinical development, manufacturing, and commercial launch, is broken into stages, with the activities, inputs, and outputs behind each stage laid out so you can see exactly what has to happen, and in what order, for a molecule to become a marketed product.

Why This Is Hard to Map From Outside

A generic prompt tends to render "R&D to commercial" as one smooth pipeline, but the real sequence is broken by hard regulatory gates — IND filing, Phase I through III, NDA/BLA submission — where the flow legally cannot proceed without clearance, and each gate resets the stakeholders, timeline, and failure risk involved. Manufacturing has a bifurcation that's easy to miss entirely: API (active ingredient) production and drug product (formulation, fill-finish) are separate value streams, frequently run at different sites or by different companies, with a quality release stage gating the handoff between them. Pharmacovigilance isn't a step at the end of the flow — it's a continuous stream that runs in parallel to commercial operations for the life of the drug and feeds back into R&D and regulatory. And market access — the payer negotiations and evidence generation that determine reimbursement — has to start years before launch, running alongside late-stage clinical development rather than after it.

Inside the Deck

22 flows spanning discovery and preclinical research, clinical development and trial operations, regulatory submission, API and drug product manufacturing, quality release, market access and pricing, commercial launch, and pharmacovigilance — each diagrammed stage by stage in PowerPoint, with the activities, inputs, and outputs documented at every stage. Every flow is fully editable, so you can adjust stages, terminology, or scope to match a specialty biologic, a generics business, or a large-molecule versus small-molecule pipeline.

Where Teams Put This to Work

• Build the business architecture baseline for an R&D IT, clinical systems, or digital transformation program
• Align two companies' clinical development or manufacturing flows during a licensing deal or M&A integration
• Onboard commercial, market access, or pharmacovigilance hires to how their function connects back to R&D and regulatory
• Brief executives on where a technology or quality-systems investment actually lands in the value chain, gate by gate

Who Should Use This

Business architecture, strategy, and transformation teams at pharmaceutical and biotech companies; R&D IT and clinical systems leaders; and consultants serving life sciences clients who need a defensible, gate-accurate map of the business rather than a generic "drug development process" slide.